Abecma Den europeiske union - norsk - EMA (European Medicines Agency)

abecma

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastiske midler - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Breyanzi Den europeiske union - norsk - EMA (European Medicines Agency)

breyanzi

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastiske midler - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Zerbaxa Den europeiske union - norsk - EMA (European Medicines Agency)

zerbaxa

merck sharp & dohme b.v.  - ceftolozane sulfat, tazobactam sodium - bakterielle infeksjoner - antibakterielle midler for systemisk bruk, - zerbaxa is indicated for the treatment of the following infections in adults:complicated intra abdominal infections;acute pyelonephritis;complicated urinary tract infections;hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap). det bør vurderes å offisielle retningslinjer for riktig bruk av antibakterielle midler.

Scheriproct 1.9 mg/ g / 5 mg/ g Norge - norsk - Statens legemiddelverk

scheriproct 1.9 mg/ g / 5 mg/ g

karo pharma ab (1) - prednisolonkaproat / cinkokainhydroklorid - rektalsalve - 1.9 mg/ g / 5 mg/ g

Inotyol Norge - norsk - Statens legemiddelverk

inotyol

viatris as - iktammol / sinkoksid / titandioksid - salve - 15 mg/ g / 150 mg/ g / 50 mg/ g

Pevaryl 1 % Norge - norsk - Statens legemiddelverk

pevaryl 1 %

karo pharma ab (1) - ekonazolnitrat - pudder - 1 %

Strefen 8.75 mg Norge - norsk - Statens legemiddelverk

strefen 8.75 mg

reckitt benckiser healthcare (scandinavia) a/s (1) - flurbiprofen - sugetablett med honning/sitronsmak - 8.75 mg

Strefen 8.75 mg/ dose Norge - norsk - Statens legemiddelverk

strefen 8.75 mg/ dose

reckitt benckiser regulatory (scandinavia) a/s - flurbiprofen - munnspray, oppløsning med peppermynte/kirsebærsmak - 8.75 mg/ dose

Strefen 8.75 mg/ dose Norge - norsk - Statens legemiddelverk

strefen 8.75 mg/ dose

reckitt benckiser healthcare (nordics) a/s - flurbiprofen - munnspray, oppløsning med honning/sitronsmak - 8.75 mg/ dose